Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, Ray KK, Parkhomenko AN, Kosiborod MN, McGuire DK, Harrington RA; THEMIS Steering Committee and Investigators. Bhatt DL, et al. Among authors: himmelmann a. Lancet. 2019 Sep 28;394(10204):1169-1180. doi: 10.1016/S0140-6736(19)31887-2. Epub 2019 Sep 1. Lancet. 2019. PMID: 31484629 Free article. Clinical Trial.
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
Bonaca MP, Bhatt DL, Simon T, Fox KM, Mehta S, Harrington RA, Leiter LA, Capell WH, Held C, Himmelmann A, Ridderstråle W, Chen J, Lee JJ, Song Y, Andersson M, Prats J, Kosiborod M, McGuire DK, Steg PG. Bonaca MP, et al. Among authors: himmelmann a. J Am Coll Cardiol. 2024 Apr 30;83(17):1627-1636. doi: 10.1016/j.jacc.2024.03.377. J Am Coll Cardiol. 2024. PMID: 38658101 Clinical Trial.
Human gut microbiome and metabolite dynamics under simulated microgravity.
Ramos-Nascimento A, Grenga L, Haange SB, Himmelmann A, Arndt FS, Ly YT, Miotello G, Pible O, Jehmlich N, Engelmann B, von Bergen M, Mulder E, Frings-Meuthen P, Hellweg CE, Jordan J, Rolle-Kampczyk U, Armengaud J, Moeller R. Ramos-Nascimento A, et al. Among authors: himmelmann a. Gut Microbes. 2023 Dec;15(2):2259033. doi: 10.1080/19490976.2023.2259033. Epub 2023 Sep 25. Gut Microbes. 2023. PMID: 37749878 Free PMC article.
Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial.
Tank A, Johnston SC, Jain R, Amarenco P, Mellström C, Rikner K, Denison H, Ladenvall P, Knutsson M, Himmelmann A, Evans SR, James S, Molina CA, Wang Y, Ouwens M. Tank A, et al. Among authors: himmelmann a. BMJ Neurol Open. 2023 Aug 24;5(2):e000478. doi: 10.1136/bmjno-2023-000478. eCollection 2023. BMJ Neurol Open. 2023. PMID: 37637218 Free PMC article.
Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency.
Szymański P, Weidinger F, Lordereau-Richard I, Himmelmann A, Arca M, Chaves J, Lee C, Jonker C, Kotecha D, O'Kelly J, Plueschke K, Ryś A, Segec A, Wallentin L, Veltrop R, James S. Szymański P, et al. Among authors: himmelmann a. Eur Heart J Qual Care Clin Outcomes. 2023 Feb 28;9(2):109-118. doi: 10.1093/ehjqcco/qcad009. Eur Heart J Qual Care Clin Outcomes. 2023. PMID: 36746430
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Heeney MM, et al. Among authors: himmelmann a. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. Blood. 2022. PMID: 35849650 Free PMC article. Clinical Trial.
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer HP, Sperb R, Stüssi G, Winkler A, Zenhäusern R, Goede JS. Rüfer A, et al. Among authors: himmelmann a. Hemasphere. 2022 Jun 17;6(7):e741. doi: 10.1097/HS9.0000000000000741. eCollection 2022 Jul. Hemasphere. 2022. PMID: 35747588 Free PMC article. No abstract available.
Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Steg PG, Bhatt DL, James SK, Darlington O, Hoskin L, Simon T, Fox KM, Leiter LA, Mehta SR, Harrington RA, Himmelmann A, Ridderstråle W, Andersson M, Bueno H, De Luca L, Tank A, Mellström C, McEwan P. Steg PG, et al. Among authors: himmelmann a. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):777-785. doi: 10.1093/ehjcvp/pvac032. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 35488865 Free PMC article. Clinical Trial.
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI.
Ducrocq G, Bhatt DL, Lee JJ, Kui N, Fox KM, Harrington RA, Leiter LA, Mehta SR, Kiss RG, James S, Vinereanu D, Huber K, Andersson M, Himmelmann A, Simon T, Steg PG. Ducrocq G, et al. Among authors: himmelmann a. Am Heart J. 2022 Jul;249:23-33. doi: 10.1016/j.ahj.2022.03.008. Epub 2022 Mar 20. Am Heart J. 2022. PMID: 35321823
204 results